Welcome to our dedicated page for Renovorx SEC filings (Ticker: RNXT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RenovoRx, Inc. (RNXT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, registration statements, and other documents filed with the U.S. Securities and Exchange Commission. RenovoRx is a life sciences company developing targeted oncology therapies and commercializing RenovoCath®, an FDA‑cleared local drug‑delivery device enabled by its patented Trans‑Arterial Micro‑Perfusion (TAMP™) therapy platform.
Through its SEC filings, RenovoRx reports financial results, commercialization progress for RenovoCath, and updates on its clinical development programs. For example, Form 8‑K filings have referenced quarterly financial press releases that discuss revenue from RenovoCath sales, expansion of cancer center customers, and advancement of the Phase III TIGeR‑PaC trial evaluating intra‑arterial gemcitabine (IAG) delivered via RenovoCath in locally advanced pancreatic cancer.
Filings also describe capital markets activity. In a Form 8‑K dated November 14, 2025, RenovoRx reported entering into a Capital on Demand™ Sales Agreement with a sales agent, allowing the company to issue and sell shares of common stock in at‑the‑market offerings or negotiated transactions under an effective shelf registration statement on Form S‑3. Related exhibits include the sales agreement and a legal opinion on the validity of the shares.
On Stock Titan, users can review these filings alongside AI‑generated highlights that help explain key sections, such as risk factor updates, financing terms, and business strategy disclosures. Investors can also monitor current reports that incorporate press releases detailing clinical milestones, registry studies, Scientific Advisory Board changes, and commercialization strategy for RenovoCath and the TAMP platform.
In addition, this page is a starting point for tracking RenovoRx’s ongoing reporting obligations, including future quarterly and annual reports, as well as any additional Forms 8‑K that may discuss clinical trial developments, capital raises, or changes in governance.
RenovoRx, Inc. announced leadership changes in its finance organization and highlighted early commercial traction for its RenovoCath device. Principal Accounting Officer Ronald B. Kocak resigned from that role on February 3, 2026, but remains Vice President and Controller with his 2026 salary unchanged.
On February 4, 2026, the board appointed consultant Mark Voll as Chief Financial Officer, serving as the company’s principal financial and accounting officer. Under a consulting agreement, he is paid $250 per hour, half in cash and half in restricted stock units, and is eligible for an initial grant of 60,000 RSUs under the 2021 Omnibus Equity Incentive Plan. A related press release notes that RenovoRx generated approximately $900,000 of RenovoCath sales revenue in the first nine months of 2025 as it transitions from purely clinical-stage activities toward commercialization.
AIGH Capital Management LLC and Orin Hirschman report a 7.1% ownership stake in Renovorx, Inc. common stock on a Schedule 13G/A (Amendment No. 2). They report beneficial ownership of 2,615,193 shares, with sole voting and sole dispositive power over all of these shares and no shared power.
The filing identifies AIGH Capital Management LLC, AIGH Investment Partners LLC, and Orin Hirschman as the reporting persons, with Hirschman serving as managing member and president of the related entities. The securities are certified as acquired and held in the ordinary course of business, and not for the purpose of changing or influencing control of Renovorx.
RenovoRx, Inc. Chief Medical Officer and director Ramtin Agah reported an open market purchase of the company’s common stock. On January 21, 2026, he bought 10,000 shares of RenovoRx common stock in open market transactions at a weighted average price of
RenovoRx, Inc. director and Chief Medical Officer Ramtin Agah reported buying 12,000 shares of the company’s common stock in an open market transaction on December 16, 2025, at a price of $0.85 per share.
After this purchase, he beneficially owns 778,460 shares of RenovoRx common stock, held directly. Agah serves as both a director and an officer, so this transaction increases his personal equity stake alongside his leadership responsibilities at the company.
RenovoRx, Inc. insider trading report: Director and Chief Medical Officer Ramtin Agah reported open market purchases of RenovoRx common stock. On 11/21/2025, he bought 10,000 shares at a price of $0.80 per share, and on 11/24/2025 he purchased an additional 12,000 shares at $0.80 per share. After these transactions, he beneficially owned 756,460 shares of RenovoRx common stock, held directly. The filing notes that these transactions reflect open market purchases of the company’s securities.
RenovoRx, Inc. entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC, allowing it to issue and sell up to $3,723,029 of common stock from time to time in at-the-market offerings or negotiated transactions. JonesTrading will act as sales agent or principal and may receive a commission of up to 3.0% of the gross sales price of any shares sold. The shares will be offered under RenovoRx’s existing Form S-3 shelf registration statement, and a newly filed Form S-3 allows continued use of that shelf for an additional 180 days past its November 21, 2025 expiration.
RenovoRx, Inc. is launching an at-the-market stock offering of up to $3,723,029 of common shares through JonesTrading. The company may sell shares from time to time, with JonesTrading acting as agent or principal and earning up to a 3% commission on gross proceeds. An illustrative scenario assumes 3,479,466 shares sold at $1.07 per share, which would increase shares outstanding from 36,649,916 to 40,129,382.
RenovoRx plans to use the net proceeds for working capital and general corporate purposes, including its Phase III TIGeR-PaC study of its IAG drug–device combination and commercialization of its FDA-cleared RenovoCath delivery device. The company is a commercial and clinical stage life sciences business focused on targeted intra-arterial chemotherapy using its TAMP platform, and is also running a post-marketing RR5 registry to evaluate RenovoCath in solid tumors.
RenovoRx (RNXT) filed a Form S-3 shelf registration to offer up to $50,000,000 of mixed securities, including common stock, preferred stock, purchase contracts, warrants, subscription rights, depositary shares, debt securities, and units, to be sold from time to time after effectiveness under Rule 415.
Offerings may occur via underwriters, dealers, agents, direct sales, or in at-the-market transactions, with terms and pricing detailed in future prospectus supplements. The company states net proceeds, if and when raised, will support working capital and general corporate purposes, including continued progression of the Phase III TIGeR-PaC study and commercial sales and marketing for the RenovoCath device.
RNXT is listed on Nasdaq Capital Market; the last reported sale price on November 12, 2025 was $1.00 per share. Shares outstanding were 36,649,916 as of November 12, 2025.
RenovoRx (RNXT) furnished an update via an 8-K stating it issued a press release announcing financial results for the quarter ended September 30, 2025. The company also included updates on its clinical trial and commercialization strategy as described in the press release.
The press release is attached as Exhibit 99.1 and incorporated by reference. RNXT’s common stock trades on the Nasdaq Capital Market under the symbol RNXT.
RenovoRx (RNXT) filed its Q3 2025 report, showing early commercial traction and continued losses as it builds out its device-led strategy. Revenue reached $266,000 for the quarter and $885,000 year‑to‑date from RenovoCath sales, producing quarterly gross profit of $213,000.
Operating expenses were $3.4 million, leading to a net loss of $2.9 million for Q3 and $8.2 million for the first nine months. Cash and cash equivalents were $10.0 million as of September 30, 2025, helped by a February underwritten offering that raised $10.8 million in net proceeds. The company reported a common stock warrant liability of $1.11 million and recorded $272,000 of inventory as it scales manufacturing under a supply agreement with $0.7 million in non‑cancellable commitments.
The company concluded current cash will not fund operations for the next 12 months from issuance, indicating a need for additional financing. Shares outstanding were 36,649,916 as of November 12, 2025.